Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis

被引：20

作者：

van Lieshout, Antoine W. T.

Popa, Calin

Meyer-Wentrup, Friederike

Lemmers, Heidi L.

Stalenhoef, Anton F.

Adema, Gosse J.

van Riel, Piet L. C. M.

van Tits, Lambertus J.

Radstake, Timothy R. D. J. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, Nijmegen, Netherlands

[2] NCMLS, Nijmegen, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands

[4] Radboud Univ Nijmegen, Med Ctr, Dept Tumor Immunol, Nijmegen, Netherlands

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2007年 / 355卷 / 02期

关键词：

CXCL16; chemokine; oxidized LDL; atherosclerosis; rheumatoid arthritis;

D O I：

10.1016/j.bbrc.2007.01.161

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

CXCL16 acts as a scavenger receptor for oxLDL in its membrane-bound form and induces migration of activated T cells in its soluble form. Due to these properties, CXCL16 has been suggested to play a role in both atherosclerosis and rheumatoid arthritis (RA). Our aim was to evaluate the contribution of soluble CXCL16 to the scavenging of oxLDL and its potential as a marker for cardiovascular disease (CVD) in patients with RA. We found that circulating CXCL16 was not correlated with plasma oxLDL or ApoB and was not related to the presence of CVD in RA patients. Moreover, CXCL16 did not bind and scavenge oxLDL in an in vitro setting. These data suggest that binding of oxLDL by soluble CXCL16 does not play a role in atherosclerosis and, although confirmation in larger studies is needed, that circulating CXCL16 is not related to the presence of CVD in patients with RA. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：392 / 397

页数：6

共 37 条

[31] Circulating oxidized low density lipoprotein levels - A biochemical risk marker for coronary heart disease [J].